Results 71 to 80 of about 35,429 (234)
Involvement of PP2A in viral and cellular transformation [PDF]
Oncogene, 2005 Although the small DNA tumor virus SV40 (simian virus 40) fails to replicate in human cells, understanding how SV40 transforms human and murine cells has and continues to provide important insights into cancer initiation and maintenance. The early region of SV40 encodes two oncoproteins: the large T (LT) and small t (ST) antigens.
Jason D, Arroyo, William C, Hahn
openaire +2 more sources
Hsp90 Inhibition on the Western Blot: N‐Terminal Versus C‐Terminal Inhibitors in Breast Cancer
Medicinal Research Reviews, EarlyView.ABSTRACT Heat shock protein 90 (Hsp90) is an established and clinically validated anticancer target. By regulating the folding and maturation of diverse client proteins, it is indirectly involved in carcinogenesis. Key breast cancer oncogenic drivers, including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, are ...
Jaka Dernovšek +3 more
wiley +1 more source
A Non-Radioactive Method for Measuring PP2A Activity in Plants
Bio-Protocol, 2015 Protein phosphatase 2A (PP2A) is a group of important cellular regulators in eukaryotes that dephosphorylate more than 30% of cellular proteins whose activities are turned on or off by phosphorylation.
Jian Chen, Guoxin Shen, Hong Zhang
doaj +1 more source
A Novel Role of PP2A Methylation in the Regulation of Tight Junction Assembly and Integrity
Frontiers in Cell and Developmental Biology, 2022 Tight junctions (TJs) are multiprotein complexes essential for cell polarity and the barrier function of epithelia. The major signaling molecule, protein serine/threonine phosphatase 2A (PP2A), interacts with the TJ and modulates the phosphorylation ...
Diana Schuhmacher +2 more
doaj +1 more source
Navigating the Complexity: A Comprehensive Review of GSK‐3 Inhibition in Regenerative Medicine
Medicinal Research Reviews, EarlyView.ABSTRACT Glycogen synthase kinase‐3 (GSK‐3) is a central regulator of numerous cellular signaling pathways, with critical roles in metabolism, proliferation, differentiation, and tissue regeneration. This review explores the multifaceted effects of pharmacological GSK‐3 inhibition across multiple body districts, focusing on its highly context‐dependent
Davide Schiroli +5 more
wiley +1 more source
Therapeutic reactivation of protein phosphatase 2A in acute myeloid leukemia
Frontiers in Oncology, 2015 Protein phosphatase 2A (PP2A) is a serine/threonine phosphatase that is required for normal cell growth and development. PP2A is a potent tumor suppressor, which is inactivated in cancer cells as a result of genetic deletions and mutations.
Kavitha eRamaswamy +2 more
doaj +1 more source
In vitro inhibition of PP2A activity with I1PP2A is prevented by memantine.
, 2016 A) The standard curve of PP2A activity assay showing linearity of the reaction up to 20 mu PP2A/assay of purified PP2A holoenzyme in dephosphorylation of tau phosphopeptide P17. B) Recombinant I1PP2A concentration-dependent inhibition of PP2A activity. C)
Xiaochuan Wang (550306) +3 more
core +1 more source
Aspartic Protease Inhibition Induces Proteomic Remodeling in Paracoccidioides brasiliensis
PROTEOMICS, EarlyView.ABSTRACT Paracoccidioidomycosis (PCM) is a major systemic mycosis in Latin America caused by Paracoccidioides brasiliensis, yet the contribution of aspartic proteases to fungal physiology and pathogenicity remains poorly understood. Here, we employed data‐independent acquisition (DIA)‐based quantitative proteomics to investigate the impact of pepstatin
Sarah Fernandes Lima +6 more
wiley +1 more source
Proteomic Analysis of PP2A Mutants and PP2A-related Tumor Virus Proteins [PDF]
, 2015 Protein phosphatase 2A (PP2A) is a tumor suppressor, whose function and activity is influenced by mutations of PP2A subunits and PP2A-related tumor virus proteins.
Zhou, Yiwang
core
Phytotherapy Research, EarlyView.ABSTRACT Vascular dementia (VaD), accounting for up to 20% of dementia cases globally, is primarily driven by chronic cerebral hypoperfusion (CCH), which leads to progressive cognitive impairment. Despite the increasing prevalence of VaD, effective treatments remain limited.
Jung‐Hoon Kim, Yongtaek Oh, Suin Cho
wiley +1 more source